Syncona Shs GBP (GB:SYNC) has released an update.
Syncona Ltd’s portfolio company Spur Therapeutics has successfully completed the Phase I/II GALILEO-1 trial for its Gaucher disease gene therapy candidate, FLT201, and plans to commence a Phase III trial in 2025. Promising results include marked biomarker improvements and positive effects on bone marrow burden, hemoglobin, platelets, and patient-reported symptoms, despite some patients developing transient antibodies. The therapy appears safe and effective, potentially redefining treatment standards for Gaucher disease.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
